Skip to main content

Table 2 The utilization of each biologic and non-biologic drug

From: Drug utilization and cost associated with inflammatory bowel disease management in Saudi Arabia

MedicationCD (N = 258)UC (N = 249)P-valueTotal (N = 507)
Biological agent, n (%) 
 Infliximab95 (36.82)28 (11.24)< 0.01*123 (24.26)
 Adalimumab53 (20.54)24 (9.64)< 0.01*77 (15.19)
 Certolizumab6 (2.33)00.036 (1.18)
 Golimumab01 (0.40)0.491 (0.20)
 Ustekinumab4 (1.55)00.124 (0.79)
 Vedolizumab2 (0.78)2 (0.80)14 (0.79)
Non-biological agents, n (%) 
 Azathioprine185 (71.71)100 (40.16)< 0.01*285 (56.21)
 Mercaptopurine03 (1.20)0.123 (0.59)
 Methotrexate7 (2.71)00.027 (1.38)
 Sulfasalazine3 (1.16)3 (1.20)16 (1.18)
 Mesalazine37 (14.34)208 (83.53)< 0.01*245 (48.32)
 Prednisone000
 Prednisolone6 (2.33)12 (4.82)0.1318 (3.55)
 Hydrocortisone3 (1.16)3 (1.20)16 (1.18)
 Budesonide9 (3.49)00.01*9 (1.78)
 Corticosteroids18 (6.98)15 (6.02)0.6633 (6.51)
 Metronidazole12 (4.65)4 (1.61)0.03*16 (3.16)
 Ciprofloxacin5 (1.94)4 (1.60)0.459 (1.78)
  1. *Indicates statistically significant difference